CA
CERE

Continuum Advisory’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Continuum Advisory’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17
Closed -$695 – 2040
2024
Q2 		$695 Hold
17
– – ﹤0.01% 1541
2024
Q1 		$719 Buy
+17
New +$714 ﹤0.01% 1535

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Continuum Advisory's CERE Position: Q3 2024 in Review

Continuum Advisory sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 17 shares — an estimated $695 sold.

Continuum Advisory first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $719 in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Continuum Advisory reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Continuum Advisory sold 17 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $695.
  • Continuum Advisory first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • Continuum Advisory's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $719 in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Continuum Advisory's 13F filing for Q3 2024, filed 15 Nov 2024.